Hope is the Air We Breathe

New Guidelines for Early Diagnosis and Treatment of Lymphangioleiomyomatosis

Lymphangioleiomyomatosis - or LAM - is a rare lung disease that usually strikes women during the prime of their lives. With the release of new clinical guidelines comes better understanding for the appropriate treatment of this debilitating illness, for both healthcare providers and patients alike. With this greater understanding comes greater hope for a cure. Just as air is vital to life, guidelines for diagnosis and treatment are vital to those living with LAM – and to the physicians working to treat them.

Treatment Guidelines

The American Thoracic Society (ATS) and the Japanese Respiratory Society (JRS), in conjunction with an ad hoc guideline development committee of LAM experts, prepared the following guidelines for the treatment of lymphangioleiomyomatosis. 


Continuing Medical Education

Lymphangioleiomyomatosis Evidence Based Practice, a new Continuing Medical Education (CME) Enduring Material activity, is now available through the joint providership of the University of Cincinnati and the RLDC for AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours), ABIM MOC Part 2 (1.00 hours). The course reviews the 2016 and 2017 ATS/JRS Clinical Practice Guidelines in addition to sharing clinical pearls from experienced LAM Clinic Directors.

This activity has been designed to meet the educational needs of pulmonologists, obstetricians and gynecologists, emergency room physicians, family medicine physicians, internal medicine physicians, nurse practitioners and physician assistants, and respiratory therapists involved in the management of patients with LAM. Clinicians can take the course and receive continuing education credits at no cost, for both CME and maintenance of certification (MOC).

Jointly provided by the University of Cincinnati and the Rare Lung Disease Consortium, this activity is supported by an independent educational grant from the UNC Eshelman Institute for Innovation as well as contributions from The LAM Foundation and the Rare Lung Disease Consortium.

To participate in this activity, please visit HTTPS://UC.CLOUD-CME.COM/APH.ASPX?EID=20754&P=3000&CASEID=2410.